Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

Titan Looking Attractive After Positive FDA Meeting

On March 3, 2014, Titan Pharmaceuticals (NASDAQ:TTNP) and commercialization partner, privately-held Braeburn Pharmaceuticals Sprl, announced they had agreed in principle with the U.S FDA on a path forward for Probuphine, an investigational subdermal implant for the maintenance treatment of opioid dependence. The news comes a few months after Titan and Braeburn attended a face-to-face meeting with the agency in November 2013. The goals of that meeting were to review and discuss existing data, and to better understand the issues of the April 2013 complete response letter. The pathway forward agreed to with the FDA centers around testing Probuphine in experienced sublingual buprenorphine patients that are "stable" on 8mg of drug daily. This is in contrast to the...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details